138 related articles for article (PubMed ID: 1511169)
1. Mullerian inhibiting substance binding and uptake.
Catlin EA; Ezzell RM; Donahoe PK; Manganaro TF; Ebb RG; MacLaughlin DT
Dev Dyn; 1992 Apr; 193(4):295-9. PubMed ID: 1511169
[TBL] [Abstract][Full Text] [Related]
2. Identification of müllerian inhibiting substance specific binding in human cell lines.
MacLaughlin DT; Levin RK; Catlin EA; Taylor LA; Preffer FI; Donahoe PK
Horm Metab Res; 1992 Dec; 24(12):570-5. PubMed ID: 1478615
[TBL] [Abstract][Full Text] [Related]
3. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK
Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763
[TBL] [Abstract][Full Text] [Related]
4. Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression.
Zhan Y; Fujino A; MacLaughlin DT; Manganaro TF; Szotek PP; Arango NA; Teixeira J; Donahoe PK
Development; 2006 Jun; 133(12):2359-69. PubMed ID: 16687449
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibody to Mullerian inhibiting substance.
Mudgett-Hunter M; Budzik GP; Sullivan M; Donahoe PK
J Immunol; 1982 Mar; 128(3):1327-33. PubMed ID: 6895760
[TBL] [Abstract][Full Text] [Related]
6. Identification of a receptor for human müllerian inhibiting substance.
Catlin EA; Ezzell RM; Donahoe PK; Gustafson ML; Son EV; MacLaughlin DT
Endocrinology; 1993 Dec; 133(6):3007-13. PubMed ID: 8243329
[TBL] [Abstract][Full Text] [Related]
7. Cleavage of Müllerian inhibiting substance activates antiproliferative effects in vivo.
Kurian MS; de la Cuesta RS; Waneck GL; MacLaughlin DT; Manganaro TF; Donahoe PK
Clin Cancer Res; 1995 Mar; 1(3):343-9. PubMed ID: 9815990
[TBL] [Abstract][Full Text] [Related]
8. Autocrine and paracrine Müllerian inhibiting substance hormone signaling in reproduction.
Ingraham HA; Hirokawa Y; Roberts LM; Mellon SH; McGee E; Nachtigal MW; Visser JA
Recent Prog Horm Res; 2000; 55():53-67; discussion 67-8. PubMed ID: 11036933
[TBL] [Abstract][Full Text] [Related]
9. Müllerian inhibiting substance inhibits branching morphogenesis and induces apoptosis in fetal rat lung.
Catlin EA; Tonnu VC; Ebb RG; Pacheco BA; Manganaro TF; Ezzell RM; Donahoe PK; Teixeira J
Endocrinology; 1997 Feb; 138(2):790-6. PubMed ID: 9003016
[TBL] [Abstract][Full Text] [Related]
10. Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression.
Clarke TR; Hoshiya Y; Yi SE; Liu X; Lyons KM; Donahoe PK
Mol Endocrinol; 2001 Jun; 15(6):946-59. PubMed ID: 11376113
[TBL] [Abstract][Full Text] [Related]
11. Involution of the female Mullerian duct of the fetal rat in the organ-culture assay for the detection of Mullerian Inhibiting Substance.
Price JM; Donahoe PK; Ito Y
Am J Anat; 1979 Oct; 156(2):265-84. PubMed ID: 506954
[TBL] [Abstract][Full Text] [Related]
12. Abnormal sexual development in transgenic mice chronically expressing müllerian inhibiting substance.
Behringer RR; Cate RL; Froelick GJ; Palmiter RD; Brinster RL
Nature; 1990 May; 345(6271):167-70. PubMed ID: 2336108
[TBL] [Abstract][Full Text] [Related]
13. The müllerian inhibitor and mammalian sexual development.
Behringer RR
Philos Trans R Soc Lond B Biol Sci; 1995 Nov; 350(1333):285-8; discussion 289. PubMed ID: 8570693
[TBL] [Abstract][Full Text] [Related]
14. Sex-specific fetal lung development and müllerian inhibiting substance.
Catlin EA; Powell SM; Manganaro TF; Hudson PL; Ragin RC; Epstein J; Donahoe PK
Am Rev Respir Dis; 1990 Feb; 141(2):466-70. PubMed ID: 2301861
[TBL] [Abstract][Full Text] [Related]
15. Müllerian inhibiting substance blocks epidermal growth factor receptor phosphorylation in fetal rat lung membranes.
Catlin EA; Uitvlugt ND; Donahoe PK; Powell DM; Hayashi M; MacLaughlin DT
Metabolism; 1991 Nov; 40(11):1178-84. PubMed ID: 1943746
[TBL] [Abstract][Full Text] [Related]
16. Effect of human recombinant mullerian inhibiting substance on isolated epithelial and mesenchymal cells during mullerian duct regression in the rat.
Tsuji M; Shima H; Yonemura CY; Brody J; Donahoe PK; Cunha GR
Endocrinology; 1992 Sep; 131(3):1481-8. PubMed ID: 1505479
[TBL] [Abstract][Full Text] [Related]
17. Minimal antiproliferative effect of recombinant müllerian inhibiting substance on gynecological tumor cell lines and tumor explants.
Wallen JW; Cate RL; Kiefer DM; Riemen MW; Martinez D; Hoffman RM; Donahoe PK; Von Hoff DD; Pepinsky B; Oliff A
Cancer Res; 1989 Apr; 49(8):2005-11. PubMed ID: 2702642
[TBL] [Abstract][Full Text] [Related]
18. Molecular biology of MIS and its receptors.
Teixeira J; Donahoe PK
J Androl; 1996; 17(4):336-41. PubMed ID: 8889695
[TBL] [Abstract][Full Text] [Related]
19. Human recombinant mullerian inhibiting substance inhibits epidermal growth factor.
Coughlin JP; Cigarroa F; Donahoe PK; McLaughlin DT
Curr Surg; 1988; 45(3):204-5. PubMed ID: 3402255
[No Abstract] [Full Text] [Related]
20. Cellular localization of müllerian inhibiting substance in the developing rat ovary.
Ueno S; Takahashi M; Manganaro TF; Ragin RC; Donahoe PK
Endocrinology; 1989 Feb; 124(2):1000-6. PubMed ID: 2643506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]